Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
about
The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathwayA dual-fluorescence high-throughput cell line system for probing multidrug resistance.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tioproninUptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analoguesThe effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceWnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathwayDi-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expressionSynthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity.Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazonesCollateral sensitivity as a strategy against cancer multidrug resistance.Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.Antitumor Agents 291 Expanded B-Ring Modification Study of 6,8,8-Triethyl Desmosdumotin B Analogues as Multidrug-Resistance Selective AgentsOverexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell linesClinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer.Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cellsAsclepiasterol, a novel C21 steroidal glycoside derived from Asclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression.Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database.Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.Is resistance useless? Multidrug resistance and collateral sensitivity.Identification of compounds selectively killing multidrug-resistant cancer cellsEngineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs.Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer.P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.
P2860
Q24322825-91A3DA51-FBA1-4B85-AC2D-B1BC9F062DF1Q33472881-0C7A9328-5968-47D3-BC2B-B3E32C8DEA39Q33763765-F18F16C1-BB00-43BD-9573-E86F60FF72CBQ33985320-1E583376-D57F-4397-80BB-A79C9DADD1B2Q34065942-B8D465AF-3F76-425D-8652-B753C9475E36Q34153747-3F9EC82E-E94A-49A7-80A8-33E4E77848C0Q34615075-67EEF07C-6C0E-4ECC-B58A-CB56BB40C754Q34774854-F6ADD556-8C1A-434B-A9BD-323CAC2DEC0BQ35067970-0CB05187-4647-4D07-9294-3C7FE5B6D34FQ35351758-37D687F5-7C58-474D-B7D5-55273BA1439AQ35406094-858EF1C2-2090-415F-9B43-DDA926D58408Q35447223-EB437312-7B26-4915-8B67-1E4C4BB7B075Q35528557-EDA7A54F-F1FA-4270-A22C-6123B10C3CE3Q35538527-FA1EA1C5-B642-4252-B674-C9D6D23CFE75Q35834576-1E8254E1-F17E-4A9D-834B-DFCD5003A508Q35928856-B99B2197-8ED5-4A57-9DA6-80C46703953CQ35946556-BE933F82-3F8A-4B73-9688-312A15C6B7FCQ36021497-30D00621-D4F9-4592-8B89-E530CDA2E4AFQ36182381-05D594D0-36E1-42C7-B7D5-62A98DF26D00Q36496944-FEF1B0F8-F76D-4A4A-B380-ECA2DB1D8CB8Q36509179-38D2E5C8-DD44-4604-B65B-13C22C71DBCDQ36556926-9125D84B-EC27-422F-A752-0D017B88D7BDQ36594649-B230B8E9-3A94-4F82-9500-8973736A2587Q37002730-2D29AA77-C483-40AD-9E22-924CB16EECC9Q37010772-CDECDD01-F807-4912-A27D-D92368241DF4Q37076348-55BBD9E7-4F95-4C4F-8D49-BCFE26549477Q37096409-FFF2AA83-E23B-40EC-92E2-E53BBA7074B1Q37199799-3D50CA41-687D-46F1-9F26-7F1962D04905Q37218015-204C281D-A375-4286-BE11-1B068E6411C0Q37285224-EB8F97DA-F1D4-462D-BFDB-37FEBBC20479Q37289000-AB1DD294-DA39-4D60-8232-430A8E592D74Q37327791-9907CAD6-30A8-45D2-B122-C1DD6796B3ECQ37330648-158A9699-CC9A-433E-88A0-C0B7C26968B2Q37347179-119EA205-2405-41AD-8AAA-D082087BCE11Q37414081-9FCE742E-7AB1-4011-AE13-84DBC1375006Q37440253-C5A3623C-47F4-4E10-A38A-4889FEB72E5EQ37507270-4153C57F-B487-4D07-BA6D-AC79E8201319Q37510528-4210988B-5B0E-467A-AF02-4A854F61685DQ37709144-7EE22DC1-5C1F-4F90-8CDF-3F50EFDE73B4Q37732337-19C95CE9-0E3A-4078-BD2B-88A368A7DE9B
P2860
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@ast
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@en
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@nl
type
label
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@ast
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@en
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@nl
prefLabel
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@ast
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@en
Selective toxicity of NSC73306 ...... ultidrug resistance in cancer.
@nl
P2093
P2860
P1433
P1476
Selective toxicity of NSC73306 ...... multidrug resistance in cancer
@en
P2093
Benjamin F Chu
Carol Cardarelli
Gergely Szakács
Henry M Fales
John N Weinstein
Joseph A Ludwig
Michael M Gottesman
Scott E Martin
Suresh V Ambudkar
Zuben E Sauna
P2860
P304
P356
10.1158/0008-5472.CAN-05-3322
P407
P577
2006-05-01T00:00:00Z